Cargando…

In Vitro Pre-validation of Gene Editing by CRISPR/Cas9 Ribonucleoprotein

BACKGROUND: The CRISPR/Cas9 genome editing system is a powerful and simple gene editing method. The format of the CRISPR components is one of the important factors in targeting efficiency. Compared to plasmid or mRNA (IVTs) format, using the CRISPR/Cas9 system as Cas9–crRNA–tracrRNA RNP format is mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehravar, Maryam, Shirazi, Abolfazl, Mehrazar, Mohammad Mehdi, Nazari, Mahboobeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Avicenna Research Institute 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626505/
https://www.ncbi.nlm.nih.gov/pubmed/31380000
_version_ 1783434581516484608
author Mehravar, Maryam
Shirazi, Abolfazl
Mehrazar, Mohammad Mehdi
Nazari, Mahboobeh
author_facet Mehravar, Maryam
Shirazi, Abolfazl
Mehrazar, Mohammad Mehdi
Nazari, Mahboobeh
author_sort Mehravar, Maryam
collection PubMed
description BACKGROUND: The CRISPR/Cas9 genome editing system is a powerful and simple gene editing method. The format of the CRISPR components is one of the important factors in targeting efficiency. Compared to plasmid or mRNA (IVTs) format, using the CRISPR/Cas9 system as Cas9–crRNA–tracrRNA RNP format is more efficient and rapid, especially in minimizing some of the pitfalls of CRISPR-mediated gene editing. In addition to efficient in vivo applications of the CRISPR RNP format in a variety of cell types and organisms, another advantage of this approach is usability for in vitro applications in which the crRNAs in the tracrRNA–crRNA structure guides the Mg2+-dependent RNAdirected DNA endonuclease to introduce double-strand breaks at specific sites in DNA. METHODS: Here, Cas9–crRNA–tracrRNA RNP system was used to test the designed crRNAs for in vitro DNA cleavage by Cas9 protein in RAG1, RAG2 and IL2RG genes. RESULTS: The results of cleavage reveal theCas9–crRNA–tracrRNA RNP system is a rapid and efficient way to pre-validate the efficiency of CRISPR cleavage with crRNAs designed for RAG1, RAG2 and IL2RG genes. CONCLUSION: one step in vitro cleavage of DNA by CRISPR/Cas9 ribonucleoprotein complex can be used to pre-validate the functionality and relative efficiency of CRISPR system for targeting genes.
format Online
Article
Text
id pubmed-6626505
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Avicenna Research Institute
record_format MEDLINE/PubMed
spelling pubmed-66265052019-08-02 In Vitro Pre-validation of Gene Editing by CRISPR/Cas9 Ribonucleoprotein Mehravar, Maryam Shirazi, Abolfazl Mehrazar, Mohammad Mehdi Nazari, Mahboobeh Avicenna J Med Biotechnol Short Communication BACKGROUND: The CRISPR/Cas9 genome editing system is a powerful and simple gene editing method. The format of the CRISPR components is one of the important factors in targeting efficiency. Compared to plasmid or mRNA (IVTs) format, using the CRISPR/Cas9 system as Cas9–crRNA–tracrRNA RNP format is more efficient and rapid, especially in minimizing some of the pitfalls of CRISPR-mediated gene editing. In addition to efficient in vivo applications of the CRISPR RNP format in a variety of cell types and organisms, another advantage of this approach is usability for in vitro applications in which the crRNAs in the tracrRNA–crRNA structure guides the Mg2+-dependent RNAdirected DNA endonuclease to introduce double-strand breaks at specific sites in DNA. METHODS: Here, Cas9–crRNA–tracrRNA RNP system was used to test the designed crRNAs for in vitro DNA cleavage by Cas9 protein in RAG1, RAG2 and IL2RG genes. RESULTS: The results of cleavage reveal theCas9–crRNA–tracrRNA RNP system is a rapid and efficient way to pre-validate the efficiency of CRISPR cleavage with crRNAs designed for RAG1, RAG2 and IL2RG genes. CONCLUSION: one step in vitro cleavage of DNA by CRISPR/Cas9 ribonucleoprotein complex can be used to pre-validate the functionality and relative efficiency of CRISPR system for targeting genes. Avicenna Research Institute 2019 /pmc/articles/PMC6626505/ /pubmed/31380000 Text en Copyright© 2019 Avicenna Research Institute http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Mehravar, Maryam
Shirazi, Abolfazl
Mehrazar, Mohammad Mehdi
Nazari, Mahboobeh
In Vitro Pre-validation of Gene Editing by CRISPR/Cas9 Ribonucleoprotein
title In Vitro Pre-validation of Gene Editing by CRISPR/Cas9 Ribonucleoprotein
title_full In Vitro Pre-validation of Gene Editing by CRISPR/Cas9 Ribonucleoprotein
title_fullStr In Vitro Pre-validation of Gene Editing by CRISPR/Cas9 Ribonucleoprotein
title_full_unstemmed In Vitro Pre-validation of Gene Editing by CRISPR/Cas9 Ribonucleoprotein
title_short In Vitro Pre-validation of Gene Editing by CRISPR/Cas9 Ribonucleoprotein
title_sort in vitro pre-validation of gene editing by crispr/cas9 ribonucleoprotein
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626505/
https://www.ncbi.nlm.nih.gov/pubmed/31380000
work_keys_str_mv AT mehravarmaryam invitroprevalidationofgeneeditingbycrisprcas9ribonucleoprotein
AT shiraziabolfazl invitroprevalidationofgeneeditingbycrisprcas9ribonucleoprotein
AT mehrazarmohammadmehdi invitroprevalidationofgeneeditingbycrisprcas9ribonucleoprotein
AT nazarimahboobeh invitroprevalidationofgeneeditingbycrisprcas9ribonucleoprotein